Explore the vast range of titles available.

Mercury's transit on the solar disk offers ideal conditions to determine the stray light level of instruments. We present here the results on the stray light level deduced from the observation of the Mercury transit on 2003 May 7th at the secondary focus of the THEMIS telescope with the broad-band and spectral channels of the IPM instrument. The scattered light in the broad-band channel is about 17% and about 25% in the spectral channel. The spread function was deduced for the two channels taking into account the observations on the limb and on Mercury's disk.The goal of this paper is to underline the limits of determining the spread function from limb measurements to correct disk observations. Indeed, we show that if a diaphragm is located in the optical path of scattering surfaces, then the spread function deduced from limb measurements can be underestimated compared to the one required for disk observations. The case is illustrated with the results of the IPM-THEMIS instrument. The spread function deduced from limb measurements is able to correct disk observations in the broad-band channel but not in the spectral channel, even if the two channels are illuminated through the same telescope configuration.

The atmospheric characterisation of hot and warm Neptune-size exoplanets is challenging due to their small radius and atmospheric scale height. The warm-Neptune HAT-P-11b is a remarkable target for such characterisation due to the large brightness of its host star (V=9.46 mag; H=7.13 mag). The aims of this work are to review the main physical and architectural properties of the HAT-P-11 planetary system, and to probe the presence of 8 molecular species in the atmosphere of HAT-P-11b at high spectral resolution in the near-infrared. The planetary system was reviewed by analysing transits and occultations of HAT-P-11b from the Kepler data set as well as HIRES at Keck archival radial-velocity (RV) data. We modelled the latter with Gaussian-process regression and a combined quasi-periodic and squared-exponential kernel to account for stellar variations on both (short-term) rotation and (long-term) activity-cycle timescales. In order to probe the atmospheric composition of HAT-P-11b, we observed 4 transits of this target with GIANO-B at TNG. We find that the long-period (\\(P\\sim9.3\\) years) RV signal previously attributed to planet HAT-P-11c is more likely due to the stellar magnetic activity cycle. Nonetheless, the Hipparcos-Gaia difference in the proper-motion anomaly suggests that an outer-bound companion might still exist. For HAT-P-11b, we measure a radius \\(R_{\\rm p}=0.4466\\pm0.0059\\,R_{\\rm J}\\), a mass \\(M_{\\rm p}=0.0787\\pm0.0048\\,M_{\\rm J}\\), and an eccentricity \\(e=0.2577^{+0.0033}_{-0.0025}\\), in accordance with values in the literature. Probing its atmosphere, we detect \\(NH_3\\) (S/N\\(=5.3\\), significance\\(=5.0\\sigma\\)) and confirm the presence of \\(H_2O\\) (S/N\\(=5.1\\), significance\\(=3.4\\sigma\\)). We also tentatively detect the signal of \\(CO_2\\) (S/N\\(=3.0\\), significance\\(=3.2\\sigma\\)) and \\(CH_4\\) (S/N\\(=4.8\\), significance\\(=2.6\\sigma\\)), whose presence need to be confirmed by further observations.

Two cases of neoplastic affections of the femur are presented, in which external fixation has been used to maintain bone alignment and limb length during the whole treatment period. Advantages and indications of the external fixation in tumors are discussed.

We have designed and built a large-throughput dual channel photometer, Diabolo. This photometer is dedicated to the observation of millimetre continuum diffuse sources, and in particular, of the Sunyaev-Zel'dovich effect and of anisotropies of the 3K background. We describe the optical layout and filtering system of the instrument, which uses two bolometric detectors for simultaneous observations in two frequency channels at 1.2 and 2.1 mm. The bolometers are cooled to a working temperature of 0.1 K provided by a compact dilution cryostat. The photometric and angular responses of the instrument are measured in the laboratory. First astronomical light was detected in March 1995 at the focus of the new Millimetre and Infrared Testa Grigia Observatory (MITO) Telescope. The established sensitivity of the system is of 7 mK_RJ s^1/2$. For a typical map of at least 10 beams, with one hour of integration per beam, one can achieve the rms values of y_SZ ~ 7 10^-5 and the 3K background anisotropy Delta T/T ~ 7 10^-5, in winter conditions. We also report on a novel bolometer AC readout circuit which allows for the first time total power measurements on the sky. This technique alleviates (but does not forbid) the use of chopping with a secondary mirror. This technique and the dilution fridge concept will be used in future scan--modulated space instrument like the ESA Planck mission project.

Introduction/BackgroundIn Argentina, 18.000 new cases of breast cancer are diagnosed each year and it is the commonest cause of cancer death in women reaching 5600 deaths per year.About 70% of all breast cancers are estrogen receptor-(ER) positive.In postmenopausal women with advanced or metastatic, ER-positive, Her2-negative breast cancer the combination of Palbociclib (P) + Letrozol (L) or Fulvestrant (F) is a good option of treatment.The objetive was to assess clinical benefit, evolution and safety with P associated with L or F in the context of daily practice.MethodologyWe performed an observational, descriptive and retrospective study.All patients who started treatment with P in combination with L or F between April 2016 and August 2019 were included.ResultsWe included 48 patients (pts), with median age 62 years (r37–85). 10 premenopausal women.26 pts (54%) performed P + L and 22 pts (46%) P + F.5 pts (10%) had metastatic onset. 22 pts (46%) visceral disease and 21 pts (44%) exclusive bone disease.Clinical benefit: 8 pts (17%) stable disease, 16 pts (34%) partial response and 3 pts (6,25%) complete response.In 23 pts (48%) an extension of 7 to 14 days of rest between cycle and cycle was necessary. Dose reduction in 12,5% (6 pts).The most frequent toxicity were neutropenia in 25 pts (52%), G3: 60%, G2: 40%, asthenia (33,3%) and fatigue (23%). No cases of febrile neutropenia were reported.Only 2 pts discontinued P because of adverse events.26 pts (54%) still under treatment.ConclusionIn our experience, the response rates observed were similar with reported data. Despite the high incidence of hematological toxicity (52% neutropenia), adherence to treatment with acceptable toxicity profile was maintained.A clinical benefit was observed in 57% of our pts with an adequate tolerance.DisclosureNothing to disclose

IntroductionIn Argentina 18.000 new cases of breast cancer (BC) are diagnosed each year and it is the commonest cause of cancer death in women reaching 5600 deaths per year.In postmenopausal women with advanced or metastatic estrogen receptor-(ER) positive, Her2-negative BC, the combination of Palbociclib (P) + Letrozol (L) or Fulvestrant (F) is a good option of treatment.The objective was to assess clinical benefit, evolution and safety with P + L or F in the context of daily clinical practice.MethodologyWe performed an observational study.Patients (pts) who started CDK4/6 inhibitors P treatment between April 2016 and June 2020 were included.Results54 pts with median age 61 years (r:31–85) were analyzed. 11 premenopausal women.29 pts (53,7%) performed P + L and 25 (46,3%) P + F.5 pts presented with the novo metastatic disease. The main localization of metastases was bone in 24 pts, lymphatic in 14, liver in 10 and lung in 6. Clinical benefit: 8 pts (14,8%) stable disease, 18 pts (33,4%) partial response and 3 pts (5,5%) complete response.Dose reduction to 100 mg P occurred in 7 pts.27 pts (50%) had cycle delays (7–14 days), mainly due to Grado 3 neutropenia (60%). Most common nonhematologic adverse events: asthenia (40%) and fatigue (35%).26 pts (48,2%) still under treatment.28 pts (51,8%) discontinued treatment, owing to disease progression in 25 pts and toxicities in 3.Conclusiona clinical benefit was observed in 48,2% of our pts with an adequate tolerance and the adherence to treatment was maintained with acceptable toxicity profile.